Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/27/15  and contains information from public web pages and contributions from the ZoomInfo community.

Founder and President

Phone: (858) ***-****  HQ Phone
Local Address:  Phoenix , Arizona , United States
International Society for Cardiovascular Translational Research
3420 South Mercy Road Suite 312
Gilbert , Arizona 85297
United States


Employment History

Board Memberships and Affiliations


  • MD
  • MSc , FACC & Cardiovascular Research Department
  • M.D.
  • degree in Master of Science , Epidemiology and Research
    Harvard School of Public Health
  • Medical Degree
    Damascus University School of Medicine
191 Total References
Web References
Celebration Stem Cell Centre, 27 Oct 2015 [cached]
Nabil Dib, MD, MSc, is director of cardiovascular research and clinical studies in cardiovascular cell therapy at Mercy Gilbert Medical Center in Gilbert, Arizona. Doing double duty as an associate professor of medicine and director of clinical CV cell therapy at the University of California, San Diego Medical Center, Dr. Dib also serves as president of the International Society for Cardiovascular Translational Research, and as co-editor and founder of its peer-reviewed journal.
Original article: Nabil Dib, MD, MSc: Generating The Future With Effective Stem Cell Therapy
ISCTR » ISCTR Governing Board, 4 Jan 2015 [cached]
Nabil Dib, MD, MSc, FACC
President, USA
Dr. Nabil Dib, M.D., MSc, FACC is one of the world's most renowned cardiovascular researchers and doctors. He completed his Interventional Cardiology Fellowship Program at Harvard Medical School, Beth-Israel-Deaconess Medical Center in Boston. Dr. Dib also completed an additional year in Investigational Devices at Harvard Medical School. Additionally, he continued his education at Harvard School of Public Health, where he obtained a degree in Master of Science in Epidemiology and Research, concentrated on a clinical trial designed and effectiveness.
He is an Associate Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy, at University of San Diego, Director of Cardiovascular Stem Cell Consultants and Heart Sciences Center, President and Founder of the International Society for Cardiovascular Translational Research (ISCTR) and Founder and Editor in Chief of the Journal of Cardiovascular Translational Research.
For more than 13 years, Dr. Dib has been conducting research and developing the newest investigational treatments for advanced cardiovascular disease. He is internationally known and respected for his research and work regarding the use of adult stem cells to restore the health of patients with severe heart disease.
Dr Dib is currently the Director of Cardiovascular Research for Mercy Gilbert and Chandler Hospitals in Gilbert, Arizona.
Stemedica - Board of Directors - Nabil Dib, 23 July 2014 [cached]
Nabil Dib, MD | Nabil Dib MD, Director, Clinical Cardiovascular Cell Therapy & Associate Professor of Medicine, University of California, San Diego
Nabil Dib, MD | Nabil Dib MD, Director, Clinical Cardiovascular Cell Therapy & Associate Professor of Medicine, University of California, San Diego
Nabil Dib
Dr Dib is Director, Clinical Cardiovascular Cell Therapy, Associate Professor of Medicine, University of California, San Diego, Director, Cardiovascular Research and New Devices, Catholic Healthcare West (Chandler Regional and Mercy Gilbert Medical Center) and Director, Cardiovascular and Stem Cell Consultants, P.C.
Dr Dib's research interests include Stem Cell Therapy for Myocardial Regeneration, Methods of Translational Stem Cell Research and Methods of Stem Cell Delivery.
Nabil Dib
CompanyNews, 17 April 2014 [cached]
LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that principal investigator Dr. Nabil Dib, M.D., M.Sc., FACC, presented results from a 23-patient study of ACT’s myoblast therapy for the treatment of congestive heart failure (CHF) over the weekend at the International Society for Cardiovascular Translational Research (ISCTR) World Symposium in San Diego, CA. Dr. Dib presented the results as a case study of the successful translation of a therapy from scientific research to the bedside. The results of the study demonstrate long term cell survival in heart failure patients as well as strong quality of life improvements as measured by the New York Heart Association third party questionnaire, the Minnesota Living with Heart Failure Questionnaire, and the 6 minute walk results (compared to continued deterioration by the control group). Moreover, ACT’s myoblast trial has been the only cell-based, FDA-approved human clinical trial that has not required the administration of anti-arrhythmic drugs or assist devices, which is in contrast to trials for bone marrow-derived and other adult stem cell therapies. ISCTR is an annual meeting for basic and clinical scientist practicing cardiovascular disease research sponsored by the University California, San Diego, Catholic Healthcare West and the International Society for Cardiovascular Translational Research. Dr. Dib is Director, Clinical Cardiovascular Cell Therapy, University of California, San Diego, and Director of Cardiovascular Research of Catholic Health Care West’s Chandler Regional Hospital and Mercy Gilbert Medical Center near, Phoenix, Arizona.
Dr. Dib enrolled 23 patients at Arizona Heart Institute with poor heart function and congestive heart failure.
â€In this study, we learned that ASM cell transplantation using a minimally invasive catheter system is safe, showed improvement in measures of quality of life, and may have the potential to improve cardiac function and electrical activity,†said Dr. Dib. By using a catheter and transplanting ASM cells into scarred tissue, new living muscle can potentially be formed with limited risk to the patient. Since the transplanted stem cells are harvested from the patient’s own skeletal muscles, the cells are compatible with the body, avoiding possible immune system and tissue compatibility complications. The procedure poses less risk than surgical procedures because no anesthesia is required and only a small incision is necessary for catheter access. Patients can be discharged within 24 hours of the procedure.
â€We are honored that the ISCTR chose our myoblast therapy as the centerpiece for discussing how best to translate research from the bench to the bedside,†stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, Inc. â€We remain encouraged by the data Dr. Dib presented and believe the positive 12-month data represent another step in our process of initiating a Phase II human clinical trial for our myoblast therapy.
Dr. Nabil Dib, an ..., 16 Oct 2007 [cached]
Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation team to advance the Myoblast Program clinical efficacy trials.
Other People with the name "Dib":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.